{"id":"NCT01657162","sponsor":"Radius Health, Inc.","briefTitle":"Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis","officialTitle":"An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-20","primaryCompletion":"2016-10-03","completion":"2016-10-03","firstPosted":"2012-08-06","resultsPosted":"2020-12-11","lastUpdate":"2020-12-11"},"enrollment":1139,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"Alendronate","otherNames":["Fosamax","Alendronate sodium"]}],"arms":[{"label":"Alendronate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).","primaryOutcome":{"measure":"Number of Participants With â‰¥1 New Vertebral Fracture Since Study BA058-05-003 Baseline","timeFrame":"Study BA058-05-003 Baseline (Day 1) up to Study BA058-05-005 Month 6 (Study BA058-05-003 Month 25)","effectByArm":[{"arm":"Abaloparatide-SC/Alendronate","deltaMin":3,"sd":null},{"arm":"Placebo/Alendronate","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States","Argentina","Brazil","Czechia","Denmark","Estonia","Hong Kong","Lithuania","Poland","Romania"]},"refs":{"pmids":["28160873","29800372","36588166","32935170","32665529","32658264","31674644","31411768"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":65,"n":553},"commonTop":["Arthralgia","Upper respiratory tract infection","Back pain","Hypertension","Pain in extremity"]}}